1
|
Liang N, Chen Y, Yang S, Liang C, Gao L, Wang S, Wang Y, Zhang Z, Shi N. Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review of Randomized Controlled Trials. Front Neurol 2022; 13:903224. [PMID: 35847214 PMCID: PMC9279622 DOI: 10.3389/fneur.2022.903224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 06/10/2022] [Indexed: 11/23/2022] Open
Abstract
Objectives This study aims to explore the benefits and harms of Chinese Herbal Medicine (CHM) for mild cognitive impairment (MCI). Methods Electronic searching was conducted in two English and four Chinese databases till 2021 December. Randomized clinical trials on CHM compared to no intervention, placebo or other therapies for MCI were included. Results Forty-nine RCTs (48 finished trials and 1 protocol) were identified. The overall methodological quality of included trials was relatively low. This review found that compared to no intervention or placebo, CHM can significantly decrease the number of patients who progressed to dementia (RR 0.36, 95% CI 0.22-0.58) and increase the cognitive function assessed by MMSE (MD 1.96, 95% CI 1.41-2.50) and MoCA (MD 2.44, 95% CI 1.57-3.31). The subgroup analysis of different CHM showed that Ginko leaf tablets can significantly improve the cognitive function compared to no intervention or placebo when assessed by MMSE (MD 2.03, 95% CI 1.18-2.88) and MoCA (MD 3.11, 95% CI 1.90-4.33). Compared to western medicine, CHM can significantly increase the score of MMSE (MD 0.88 95% CI 0.46-1.30) and MoCA (MD 0.87, 95% CI 0.33-1.41), but there was no significant difference on the score of ADL (SMD -0.61, 95% CI -1.49 to 0.27). None of the RCTs reported on the quality of life. Of 22 RCTs that reported adverse events, there was no statistical difference between the CHM and the control group. Conclusions CHM, Ginko leaf extracts in particular, could help to prevent progression into dementia and to improve cognitive function and ability of daily living activities. More qualified RCTs were needed to confirm the conclusion due to the low quality of current trials. Systematic Review Registration Unique Identifier: CRD42020157148.
Collapse
Affiliation(s)
- Ning Liang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yaxin Chen
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Sihong Yang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Changhao Liang
- Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
| | - Lidong Gao
- College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Shang Wang
- College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Yanping Wang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Zhanjun Zhang
- State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China
| | - Nannan Shi
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
- State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China
| |
Collapse
|
2
|
Effects of Adjuvant Chinese Patent Medicine Therapy on Prevention of Variceal Rebleeding: A Retrospective Cohort Study. Chin J Integr Med 2020; 27:589-596. [PMID: 32876859 DOI: 10.1007/s11655-020-3272-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To assess whether adjuvant Chinese patent medicines (CPMs) to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients. METHODS This study retrospectively collected 555 consecutive patients who recovered from variceal bleeding. A population-based cohort study was established depending on if adjuvant CPMs were administered to prevent rebleeding. A total of 139 patients who had taken ⩾28 cumulative defined daily doses (cDDDs) of CPMs were included in the CPMs cohort, and 416 patients who used <28 cDDDs of CPMs were enrolled in the non-CPMs cohort. On evaluation of rebleeding incidence, 1:2 propensity score matched was used to estimate for reducing bias. Patients were followed for at least 12 months. The end-point of this study was clinically significant esophagogastric variceal rebleeding. RESULTS Following multivariate analysis, CPMs therapy was an independent factor for variceal rebleeding [adjusted hazard ratio (AHR)=0.657; 95% confidence interval=0.497-0.868; P=0.003]. After the 1:2 propensity score matching, a significant reduction (23.5%) in the incidence of variceal rebleeding in patients was observed, from 58.3% in the non-CPMs cohort to 44.6% in the CPMs cohort (modified log-rank test, P=0.002) within a year. The AHRs for rebleeding were 0.928, 0.553, and 0.105, for 28-90 cDDDs, 91-180 cDDDs, and >180 cDDDs of CPMs, respectively. The median rebleeding interval in the CPMs cohort was significantly larger compared with the non-CPMs cohort (113.5 vs. 93.0 days; P=0.008). CONCLUSION Adjuvant CPMs to standard therapy can significantly reduce the incidence of variceal rebleeding and delay the time to rebleeding.
Collapse
|
3
|
Li XK, Zhang MX, Shao FZ, Zhou DQ, Xue JD, Liu TJ, Chi XL, Lu BJ, Wang XB, Li Q, Li J, Mao DW, Yang HS, Yang HZ, Zhao WX, Li Y, Zhang GL, Zhao YM, Zou JD, Liu MY, Zhang KK, Yang XZ, Gan DN, Li Y, Zhang P, Li ZG, Li S, Ye YA. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial. Chin J Integr Med 2020; 26:330-338. [PMID: 31919749 DOI: 10.1007/s11655-020-3250-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To evaluate the effects of a 48-week course of adefovir dipivoxil (ADV) plus Chinese medicine (CM) therapy, namely Tiaogan Jianpi Hexue () and Tiaogan Jiedu Huashi () fomulae, in hepatitis B e antigen (HBeAg)-positive Chinese patients. METHODS A total of 605 HBeAg-positive Chinese CHB patients were screened and 590 eligible participants were randomly assigned to 2 groups in 1:1 ratio including experimental group (EG, received ADV plus CM) and control group (CG, received ADV plus CM-placebo) for 48 weeks. The major study outcomes were the rates of HBeAg and HBV-DNA loss on week 12, 24, 36, 48, respectively. Secondary endpoints including liver functions (enzymes and bilirubin readings) were evaluated every 4 weeks at the beginning of week 24, 36, and 48. Routine blood, urine, and stool analyses in addition to electrocardiogram and abdominal B scan were monitored as safety evaluations. Adverse events (AEs) were documented. RESULTS The combination therapy demonstrated superior HBeAg loss at 48 weeks, without additional AEs. The full analysis population was 560 and 280 in each group. In the EG, population achieved HBeAg loss on week 12, 24, 36, and 48 were 25 (8.90%), 34 (12.14%), 52 (18.57%), and 83 (29.64%), respectively; the equivalent numbers in the CG were 20 (7.14%), 41 (14.64%), 54 (19.29%), and 50 (17.86%), respectively. There was a statistically significant difference between these group values on week 48 (P<0.01). No additional AEs were found in EG. Subgroup analysis suggested different outcomes among treatment patterns. CONCLUSION Combination of CM and ADV therapy demonstrated superior HBeAg clearance compared with ADV monotherapy. The finding indicates that this combination therapy may provide an improved therapeutic effect and safety profile (ChiCTR-TRC-11001263).
Collapse
Affiliation(s)
- Xiao-Ke Li
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Ming-Xiang Zhang
- Department of Hepatology, the Sixth People's Hospital of Shenyang, Shenyang, 110006, China
| | - Feng-Zhen Shao
- Department of Hepatology, the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300000, China
| | - Da-Qiao Zhou
- Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033, China
| | - Jing-Dong Xue
- Department of Hepatology, Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, 710003, China
| | - Tie-Jun Liu
- Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Xiao-Ling Chi
- Department of Hepatology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, 510006, China
| | - Bing-Jiu Lu
- Department of Hepatology, Liaoning Hospital of Traditional Chinese Medicine, Shenyang, 110032, China
| | - Xian-Bo Wang
- Department of Hepatology, Beijing Ditan Hospital, Beijing, 100015, China
| | - Qin Li
- Department of Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
| | - Jun Li
- Department of Hepatology, the 302 Military Hospital of PLA, Beijing, 100039, China
| | - De-Wen Mao
- Department of Hepatology, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China
| | - Hua-Sheng Yang
- Department of Integrated Traditional Chinese Medicine and Western Medicine, Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China
| | - Hong-Zhi Yang
- Department of Traditional Chinese Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Wen-Xia Zhao
- Department of Gastroenterology, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China
| | - Yong Li
- Department of Hepatology, Shandong Hospital of Traditional Chinese Medicine, Jinan, 250011, China
| | - Guo-Liang Zhang
- Department of Gastroenterology, Anhui Hospital of Traditional Chinese Medicine, Hefei, 230031, China
| | - Yi-Ming Zhao
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China
| | - Jian-Dong Zou
- Clinical Research Center, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, 210029, China
| | - Meng-Yang Liu
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Ke-Ke Zhang
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Xian-Zhao Yang
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Da-Nan Gan
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Ying Li
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Peng Zhang
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Zhi-Guo Li
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Shuo Li
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Yong-An Ye
- Department of Gastroenterology, Institute of Liver Disease, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China.
| |
Collapse
|
4
|
Wang Q, Li C, Di S, Han L, Zhao L, Tong X. Clinical efficacy and safety of traditional Chinese patent medicine for hyperthyroid heart disease: study protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13076. [PMID: 30407305 PMCID: PMC6250447 DOI: 10.1097/md.0000000000013076] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Hyperthyroid heart disease (HHD), one of the most common complications of hyperthyroidism, is a serious public health problem due to the direct toxic or indirect effects of excessive thyroid hormone on the heart, resulting in high mortality and increasing health care costs. Traditional Chinese patent medicines (TCPMs), developed by combining modernized pharmaceutical technologies with ancient TCM theories, have been widely used in the treatment of HHD. However, the safety and efficacy of TCPMs used in patients with HHD has been uncertain and there has been no standard clinical trial published to confirm this. Thus, we conduct a study to evaluate the safety and efficacy of TCPMs for HHD. METHODS The reference lists of randomized controlled trials and 8 electronic databases will be independently and systematically searched by 2 review authors in August 2018. Four English databases [EMBASE, PubMed, National Guideline Clearinghouse (NGC), and Cochrane Central Register of Controlled Trials (CENTRAL)] and 4 Chinese databases [Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure [CNKI], Wanfang Database, and VIP Database] will be included. The primary outcomes will be assessed according to the effective rate of treatment, electrocardiogram, and thyroid hormone levels. Data synthesis will be precisely computed using the RevManV5.3 software when a data-analysis is allowed. Methodological quality will be assessed according to Cochrane Handbook. RESULTS This study will provide a high-quality synthesis of current evidence of TCPMs for HHD from different aspects, including the clinical symptoms, thyroid hormone levels, and ECG changes. CONCLUSION The conclusion of this systematic review will provide evidence to prove whether TCPMs are effective therapeutic intervention for patient with HHD.
Collapse
Affiliation(s)
- Qing Wang
- Guang’anmen Hospital of China Academy of Chinese Medical Sciences
- Beijing University of Chinese Medicine
| | - Chun Li
- Beijing University of Chinese Medicine
- Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China
| | - Sha Di
- Guang’anmen Hospital of China Academy of Chinese Medical Sciences
| | - Lin Han
- Guang’anmen Hospital of China Academy of Chinese Medical Sciences
| | - Linhua Zhao
- Guang’anmen Hospital of China Academy of Chinese Medical Sciences
| | - Xiaolin Tong
- Guang’anmen Hospital of China Academy of Chinese Medical Sciences
| |
Collapse
|
5
|
Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018; 24:653-660. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2018] [Indexed: 12/22/2022]
Abstract
BACKGROUND The domestic prevalence of chronic hepatitis B (CHB) in China is 7.18% in 2006, imposing great societal healthcare burdens. Nucleot(s)ide analogues (NUCs) anti-hepatitis B virus (HBV) therapies are widely applied despite the relatively low rate of seroconversion and high risk of drug-resistant mutation. More effective treatments for CHB deserve further explorations. Combined therapy of NUCs plus Chinese herbal medicine (CHM) is widely accepted in China, which is recognized as a prospective alternative approach. The study was primarily designed to confirm the hypothesis that Tiaogan-Yipi Granule (, TGYP) or Tiaogan-Jianpi-Jiedu Granule (, TGJPJD) plus entecavir tablet (ETV) was superior over ETV monotherapy in enhancing HBeAg loss rate. METHODS The study was a nationwide, large-scale, multi-center, double-blind, randomized, placebo-controlled trial with a designed duration of 108 weeks. A total of 16 hospitals and 596 eligible Chinese HBeAg positive CHB patients were enrolled from November 2012 to September 2013 and randomly allocated into 2 groups in 1:1 ratio via central randomization system: experimental group (EG) and control group (CG). Subjects in EG received CM formulae (TGYP or TGJPJD, 50 g per dose, twice daily) plus ETV tablet (or ETV placebo) 0.5 mg per day in the first 24 weeks (stage 1), and CHM granule plus ETV tablet (0.5 mg per day) from week 25 to 108 (stage 2). Subjects in CG received CHM Granule placebo plus ETV tablet (0.5 mg per day) for 108 weeks throughout the trial. The assessments of primary outcomes (HBV serum markers and HBV-DNA) were conducted by a third-party College of American Pathologists (CAP) qualified laboratory. Adverse effects were observed in the hospitals of recruitment. DISCUSSION The study was designed to compare the curative effect of CM plus ETV and ETV monotherapy in respect of HBeAg loss, which is recognized by the European Association for the Study of the Liver as "a valuable endpoint". We believe this trial could provide a reliable status for patients' "journey" towards durable responses after treatment discontinuation. The trial was registered before recruitment on Chinese Clinical trial registry (No. ChiCTR-TRC-12002784, Version 1.0, 2015/12/23).
Collapse
Affiliation(s)
- Yong-An Ye
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China.
| | - Xiao-Ke Li
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Da-Qiao Zhou
- Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong Province, 518033, China
| | - Xiao-Ling Chi
- Department of Hepatology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, 510006, China
| | - Qin Li
- Department of Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
| | - Li Wang
- Department of Hepatology, Public Health Clinical Center of Chengdu, Chengdu, 610066, China
| | - Bing-Jiu Lu
- Department of Hepatology, Liaoning Hospital of Traditional Chinese Medicine, Shenyang, 110032, China
| | - De-Wen Mao
- Department of Hepatology, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China
| | - Qi-Kai Wu
- Department of Hepatology, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong Province, 518112, China
| | - Xian-Bo Wang
- Department of Hepatology, Beijing Ditan Hospital, Beijing, 100015, China
| | - Ming-Xiang Zhang
- Department of Hepatology, the Sixth People's Hospital of Shenyang, Shenyang, 110006, China
| | - Jing-Dong Xue
- Department of Hepatology, Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, 710003, China
| | - Yong Li
- Department of Hepatology, Shandong Hospital of Traditional Chinese Medicine, Jinan, 250011, China
| | - Wei Lu
- Department of Hepatology, the Second People's Hospital of Tianjin, Tianjin, 300000, China
| | - Jian-Chun Guo
- Department of Hepatology, Xixi Hospital of Hangzhou, Hangzhou, 310023, China
| | - Feng Jiang
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Xin-Wei Zhang
- Department of Hepatology, 302 Military Hospital of China, Beijing, 100039, China
| | - Hong-Bo Du
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Xian-Zhao Yang
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Hui Guo
- Department of Hepatology, the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300000, China
| | - Da-Nan Gan
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Zhi-Guo Li
- Institute of Liver Diseases, Beijing University of Chinese Medicine, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| |
Collapse
|
6
|
Pang B, Lian FM, Zhao XY, Zhao XM, Jin D, Lin YQ, Zheng YJ, Ni Q, Tong XL. Prevention of type 2 diabetes with the traditional Chinese patent medicine: A systematic review and meta-analysis. Diabetes Res Clin Pract 2017; 131:242-259. [PMID: 28780370 DOI: 10.1016/j.diabres.2017.07.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 06/13/2017] [Accepted: 07/07/2017] [Indexed: 12/11/2022]
Abstract
AIM Early interventions in prediabetes can prevent or delay the incidence of type 2 diabetes mellitus (T2DM). The aim of this review was to assess the efficacy and safety of traditional Chinese patent medicine (TCPM) on the prevention of T2DM. METHODS Seven electronic databases were searched to identify eligible trials published until June 1, 2016. Randomized controlled trials (RCTs) that compared TCPM plus lifestyle modification (LM) versus LM alone were included for in the. RCTs that used TCPM plus LM compared with placebo plus LM were also included. Methodological quality was assessed using the Cochrane Collaboration Risk of Bias tool. A random- or fixed-effect model was used to analyze outcomes that were expressed as risk ratios (RRs) or mean differences (MD), and the I2 statistic was used to assess heterogeneity. RESULTS Twenty-six trials with a total of 4169 participants met the inclusion criteria. Subgroup analysis confirmed that, compared with LM alone, TCPM and LM together were significantly better at reducing diabetes (RR, 0.47; 95% CI, 0.38-0.59) and normalizing blood glucose (RR, 0.76; 95% CI, 0.69-0.85). They also caused a greater reduction in fasting plasma glucose (FBG) (MD, -0.37; 95% CI, -0.62 to -0.13), 2-h plasma glucose (2h PG) (MD, -0.91; 95% CI, -1.35 to -0.47) and body mass index (BMI) (MD, -0.45; 95% CI, -0.76 to -0.14). Compared with placebo plus LM, TCPM plus LM was superior at reducing diabetes (RR, 0.55; 95% CI, 0.45-0.68) and normalizing blood glucose (RR, 0.62; 95% CI, 0.50-0.76). The interventions were also associated with a decline in FBG levels (MD, -0.68; 95% CI, -1.25 to -0.11) and 2h PG levels (MD, -1.07; 95% CI, -1.85 to -0.29). There were no significant differences in adverse events in either group. Subgroup and sensitivity analyses found no significant difference in overall effects among all study characteristics, indicating that the overall effects were stable. Generally, the quality of evidence was low for the effect of TCPM on the incidence of diabetes and normalization of blood glucose, and was very low for the effects of TCPM on FBG, 2h PG, and BMI. CONCLUSIONS Based on this systematic review, TCPM may reduce the risk of progression to T2DM and increase the possibility of regression toward normoglycemia. As a result of the methodological drawbacks of the included studies, more rigorously designed RCTs are required to more reliably assess the efficacy of TCPM and long-term follow-up is needed before TCPM can be recommended for prediabetic patients.
Collapse
Affiliation(s)
- Bing Pang
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
| | - Feng-Mei Lian
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
| | - Xi-Yan Zhao
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
| | - Xue-Min Zhao
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China; Beijing University of Chinese Medicine, Beijing 100029, China
| | - De Jin
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
| | - Yi-Qun Lin
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China; Beijing University of Chinese Medicine, Beijing 100029, China
| | - Yu-Jiao Zheng
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China; Beijing University of Chinese Medicine, Beijing 100029, China
| | - Qing Ni
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China.
| | - Xiao-Lin Tong
- Department of Endocrinology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China.
| |
Collapse
|
7
|
Ye YA, Tian DL, Jiang J, Li J, Chen JJ, Li ZH, Ma WG, Zhao YM, Wang RB, Yang SZ, Shao FZ, Ji G, Zhou DQ, Liu TJ, Cheng DS, Zhang W, Sun KW, Wang YF, Min LQ, Li XK. Effect of Shuanghu Qinggan Granule () and Yigan Yiqi Jieyu Granule () plus lamivudine on chronic hepatitis B patients: A randomized double-blind placebo-controlled trial. Chin J Integr Med 2016:10.1007/s11655-016-2519-9. [PMID: 27933509 DOI: 10.1007/s11655-016-2519-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2013] [Indexed: 10/20/2022]
Abstract
OBJECTIVE To observe the clinical efficacy and safety of Shuanghu Qinggan Granule ( , SQG) plus Yigan Yiqi Jieyu Granule (, YYJG) combined with lamivudine (LAM) on chronic hepatitis B (CHB) patients. METHODS The study was a multicenter, randomized, double-blinded and parallel controlled trial. A total of 320 patients were randomly allocated into 2 groups equally: 160 patients (treatment group) were given SQG and YYJG combined with LAM; and 160 patients (control group) were given LAM plus Chinese herb placebo, respectively. Liver functions, hepatitis B envelop antigen (HBeAg) titer levels, and hepatitis B virus DNA (HBV-DNA) load were monitored. RESULTS (1) In the 48th week, the treatment group showed superior HBeAg seroconversion rate than that in the control group (38.0% vs. 24.0%, P<0.05). (2) In the 48th week, the treatment group demonstrated lower HBeAg titer than that in the control group (P<0.05). (3) In the 12th, 24th, 48th week, there was no statistical significance in HBV-DNA response rate between the two groups. (4) In the 12th week, the level of glutamyl transpeptidase (GGT) was significantly decreased in the treatment group compared with the control group (P<0.05); in the 36th week, the levels of alanine aminotransferase and aspartate transaminase were significantly lower in the treatment group than those in the control group (P<0.05). CONCLUSION The protocol of SQG and YYJG combined with LAM to treat CHB showed superior efficacy than LAM monotherapy.
Collapse
Affiliation(s)
- Yong-An Ye
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China.
| | - De-Lu Tian
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Jian Jiang
- Department of Hepatology, Shanghai Shuguang Hospital, Shanghai, 201210, China
| | - Jun Li
- Department of Integrated Chinese and Western Medicine, 302 Military Hospital of China, Beijing, 100039, China
| | - Jian-Jie Chen
- Department of Hepatology, Shanghai Shuguang Hospital, Shanghai, 201210, China
| | - Zhi-Hong Li
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Wei-Guo Ma
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Yi-Ming Zhao
- Epidemic Research Center, The Third Hospital Affiliated to Peking University, Beijing, 100191, China
| | - Rong-Bing Wang
- Department of Integrated Chinese and Western Medicine, Beijing Ditan Hospital, Beijing, 100015, China
| | - Shi-Zhong Yang
- Department of Hepatology, Hospital Affiliated to Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Feng-Zhen Shao
- Department of Hepatology, The First Hospital Affiliated to Tianjin University of Chinese Medicine, Tianjin, 300193, China
| | - Guang Ji
- Department of Hepatology, Shanghai Longhua Hospital, Shanghai, 200032, China
| | - Da-Qiao Zhou
- Department of Hepatology, Shenzhen Hospital of Chinese Medicine, Shenzhen, Guangdong province, 581033, China
| | - Tie-Jun Liu
- Department of Hepatology, Hospital Affiliated to Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Dong-Sheng Cheng
- Department of Hepatology, Shaanxi Provincial Hospital of Chinese Medicine, Xi'an, 710003, China
| | - Wei Zhang
- Department of Hepatology, Shanghai Longhua Hospital, Shanghai, 200032, China
| | - Ke-Wei Sun
- Department of Hepatology, The First Hospital Affiliated to Hunan University of Chinese Medicine, Changsha, 410007, China
| | - Yu-Fen Wang
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| | - Le-Quan Min
- School of Applied Science and Information Engineering, Beijing University of Science and Technology, Beijing, 100083, China
| | - Xiao-Ke Li
- Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, 100700, China
| |
Collapse
|